Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
Modified-Release Drug Delivery Systems: Rate-Programmed II01:19

Modified-Release Drug Delivery Systems: Rate-Programmed II

Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
Bioavailability Enhancement: Drug Permeability Enhancement01:27

Bioavailability Enhancement: Drug Permeability Enhancement

After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dual LC column characterization for mass spectrometry-based small molecule profiling of human plasma and serum.

Analytica chimica acta·2025
Same author

Preparation and Complex Characterisation of Stabilised Gold Nanoparticles: Biodistribution and Application for High Resolution In Vivo Imaging.

Pharmaceuticals (Basel, Switzerland)·2024
Same author

Long circulating liposomal platform utilizing hydrophilic polymer-based surface modification: preparation, characterisation, and biological evaluation.

International journal of pharmaceutics·2024
Same author

Carbon-Based Nanomaterials Increase Reactivity of Primary Monocytes towards Various Bacteria and Modulate Their Differentiation into Macrophages.

Nanomaterials (Basel, Switzerland)·2021
Same author

Overexpression of CD44v8-10 in Colon Polyps-A Possible Key to Early Diagnosis.

Pathology oncology research : POR·2021
Same author

Myomedin scaffold variants targeted to 10E8 HIV-1 broadly neutralizing antibody mimic gp41 epitope and elicit HIV-1 virus-neutralizing sera in mice.

Virulence·2021
Same journal

Endogenous-metabolite-inspired polyamine-oleic acid lipids for safe mRNA delivery and PCSK9 gene editing.

Journal of controlled release : official journal of the Controlled Release Society·2026
Same journal

Tunable rigid spikes on virus-like porous silica enable mechanistically controlled nanovaccine platforms.

Journal of controlled release : official journal of the Controlled Release Society·2026
Same journal

Metabolic regulation-driven nanoparticles for tumor vulnerabilization and enhanced photodynamic therapy.

Journal of controlled release : official journal of the Controlled Release Society·2026
Same journal

New approach methodologies (NAMs) for preclinical and translational evaluation of mRNA-lipid nanoparticle (LNP) therapeutics.

Journal of controlled release : official journal of the Controlled Release Society·2026
Same journal

A cation-free platform based on azocalixarene poly(disulfide)s for direct cytosolic protein delivery.

Journal of controlled release : official journal of the Controlled Release Society·2026
Same journal

Harnessing plant-derived extracellular vesicles for oral delivery: A dual role as natural therapeutics and engineered drug carriers.

Journal of controlled release : official journal of the Controlled Release Society·2026
See all related articles

Related Experiment Video

Updated: May 18, 2026

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles
09:56

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles

Published on: August 2, 2016

Liposomal paclitaxel formulations.

Stěpán Koudelka1, Jaroslav Turánek

  • 1Department of Toxicology, Pharmacology and Immunotherapy, Veterinary Research Institute, Brno, Czech Republic.

Journal of Controlled Release : Official Journal of the Controlled Release Society
|September 20, 2012
PubMed
Summary
This summary is machine-generated.

Liposomal paclitaxel (PTX) offers improved safety and efficacy over traditional Taxol for cancer treatment. This review covers 30 years of liposomal PTX development, including clinical trials and targeted delivery systems.

More Related Videos

Facile Preparation of Internally Self-assembled Lipid Particles Stabilized by Carbon Nanotubes
09:47

Facile Preparation of Internally Self-assembled Lipid Particles Stabilized by Carbon Nanotubes

Published on: February 19, 2016

Related Experiment Videos

Last Updated: May 18, 2026

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles
09:56

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles

Published on: August 2, 2016

Facile Preparation of Internally Self-assembled Lipid Particles Stabilized by Carbon Nanotubes
09:47

Facile Preparation of Internally Self-assembled Lipid Particles Stabilized by Carbon Nanotubes

Published on: February 19, 2016

Area of Science:

  • Oncology
  • Drug Delivery Systems
  • Nanotechnology

Background:

  • Taxanes, particularly paclitaxel (PTX), are crucial in cancer chemotherapy.
  • Commercial PTX (Taxol®) causes significant side effects and hypersensitivity reactions.
  • Liposomes offer advanced drug delivery, improving drug tolerability and efficacy.

Purpose of the Study:

  • To review the development of liposomal paclitaxel (PTX) formulations over the past three decades.
  • To discuss advancements in targeted liposomal PTX systems.
  • To summarize the progress of liposomal PTX in clinical trials.

Main Methods:

  • Review of scientific literature on liposomal paclitaxel.
  • Analysis of in vivo mouse tumor models and human clinical trial data.
  • Examination of various liposomal formulation preparation techniques.

Main Results:

  • Liposomal PTX formulations demonstrate a significantly higher maximum tolerated dose (MTD) compared to Taxol®.
  • Several liposomal PTX formulations are in various clinical trial phases (e.g., LEP-ETU, EndoTAG®-1 in Phase II).
  • One liposomal PTX formulation (Lipusu®) has been commercialized, indicating clinical success.

Conclusions:

  • Liposomal paclitaxel represents a significant advancement in cancer treatment, offering improved safety and efficacy.
  • Continued research and development in liposomal PTX formulations and targeted delivery systems show promise.
  • The commercialization and clinical progression of liposomal PTX highlight its therapeutic potential.